Journal Article Summary
The article discusses the development of a new intravaginal ring (IVR) designed to help women prevent HIV-1, HSV-2, HPV, and unintended pregnancies. This topic is significant because women, especially in low-income regions, face high risks of these infections and unintended pregnancies, which can severely impact their health and well-being. Current prevention methods often do not address multiple risks simultaneously, highlighting the need for a multipurpose prevention technology (MPT) that women can initiate themselves.
The researchers created a core-matrix IVR that contains four active ingredients: MIV-150 (targeting HIV), zinc acetate (for HIV and HSV-2), carrageenan (for HPV and HSV-2), and levonorgestrel (for contraception). The IVR was tested in vitro for up to 94 days and in vivo in macaques for about 28 days. The results showed that the IVR effectively released these ingredients over time, maintaining their antiviral activity against HIV-1, HSV-2, and HPV, while also providing contraceptive effects.
However, the study has limitations, including the small sample size of macaques and variability in the release of active ingredients due to physiological factors. Patients should consult healthcare professionals about the potential benefits and risks of using such an IVR, especially if they are in high-risk groups for these infections. It is essential to discuss any new prevention methods with a healthcare provider to ensure they are appropriate for individual health needs and circumstances.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Ugaonkar Shweta R., Wesenberg Asa, Wilk Jolanta, Seidor Samantha, Mizenina Olga, Kizima Larisa, Rodriguez Aixa, Zhang Shimin, et al.. A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy. Journal of controlled release : official journal of the Controlled Release Society 2015. DOI: 10.1016/j.jconrel.2015.06.018. PMID: 26091920. PMCID: PMC4683108.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
